Efalizumab Therapy for Psoriasis in Patients with Inadequate Responses to Etanercept

In this: publication
By this: publisher
In this Subject: Dermatology
By this author: Kramer, Jesse M. ;&nbsp; Turner, James E.

Authors: Kramer, Jesse M.¹; Turner, James E.²

Source: American Journal of Clinical Dermatology, Volume 10, Number 2, 2009 , pp. 134-140(7)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

Efalizumab is a recombinant humanized monoclonal antibody approved for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. We present six cases of favorable response to efalizumab therapy in patients with psoriasis who demonstrated inadequate response or who were non-responders to treatment with etanercept, a tumor necrosis factor-α-binding fusion protein. The subsequent response of these patients suggests that efalizumab may be a viable treatment option for patients with psoriasis who respond poorly to etanercept.

Document Type: Research article

Affiliations: 1: 1 Dermatology Division, Mercy Medical Group, Sacramento, California, USA 2: 2 Mid-South Dermatology and Skin Cancer Center, Memphis, Tennessee, USA

Publication date: 2009-01-01